"These factors are enormously important in the course of medical treatment, but are almost always assessed through infrequent and after the fact self-reports," he added. "To have these data in near-continuous form will greatly expand our understanding of who does well on what treatment, when, why and for how long."
The Calit2 researchers are partnering with The University of Texas M. D. Anderson Cancer Center the nation's foremost institute for clinical cancer care on the $3.86 million Grand Opportunity grant. The multidisciplinary consortium of investigators will first determine the parameters of the project and then create the prototype cyberinfrastructure for data aggregation, integration, processing, mining, storage and retrieval.
Once the data acquisition systems and software have been developed, the M. D. Anderson team will beta-test the prototype in clinical trials. Another thrust of the project will be to develop related applications for the cyberinfrastructure, including a Web-based user interface, home and mobile phone-based sensing devices to gather real-time patient data, and the use of novel brain-based device methods for data analysis.
"CYCORE could be used across the whole spectrum of oncology research," says Wendy Demark-Wahnefried, a professor of behavioral science at The University of Texas and a co-principal investigator on the project. "It will allow us an opportunity to study various factors that heretofore we have not been able to study, such as the role that diet plays, or supplements, or secondhand smoke. It's hard to capture those data and that's why we need the expertise of the researchers at Calit2. As the CYCORE system expands in size and scope, the oncology community could upload the data from a vast number of clinical trials. By having more data points we'll be able to better create models for prevention, treatment and recov
|Contact: Doug Ramsey|
University of California - San Diego